HMGB1-C1q complexes regulate macrophage function by switching between leukotriene and specialized proresolving mediator biosynthesis.
Animals
Arachidonate 5-Lipoxygenase
/ metabolism
Complement C1q
/ metabolism
HMGB1 Protein
/ metabolism
Interferon Regulatory Factors
/ metabolism
Leukotriene B4
/ biosynthesis
Macrophages
/ physiology
Mice, Inbred C57BL
Monocytes
/ metabolism
Peritonitis
/ chemically induced
Receptor for Advanced Glycation End Products
/ metabolism
Receptors, Immunologic
/ metabolism
C1q
HMGB1
IRF5
SPMs
leukotriene
Journal
Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876
Informations de publication
Date de publication:
12 11 2019
12 11 2019
Historique:
pubmed:
2
10
2019
medline:
2
4
2020
entrez:
2
10
2019
Statut:
ppublish
Résumé
Macrophage polarization is critical to inflammation and resolution of inflammation. We previously showed that high-mobility group box 1 (HMGB1) can engage receptor for advanced glycation end product (RAGE) to direct monocytes to a proinflammatory phenotype characterized by production of type 1 IFN and proinflammatory cytokines. In contrast, HMGB1 plus C1q form a tetramolecular complex cross-linking RAGE and LAIR-1 and directing monocytes to an antiinflammatory phenotype. Lipid mediators, as well as cytokines, help establish a milieu favoring either inflammation or resolution of inflammation. This study focuses on the induction of lipid mediators by HMGB1 and HMGB1 plus C1q and their regulation of IRF5, a transcription factor critical for the induction and maintenance of proinflammatory macrophages. Here, we show that HMGB1 induces leukotriene production through a RAGE-dependent pathway, while HMGB1 plus C1q induces specialized proresolving lipid mediators lipoxin A4, resolvin D1, and resolvin D2 through a RAGE- and LAIR-1-dependent pathway. Leukotriene exposure contributes to induction of IRF5 in a positive-feedback loop. In contrast, resolvins (at 20 nM) block IRF5 induction and prevent the differentiation of inflammatory macrophages. Finally, we have generated a molecular mimic of HMGB1 plus C1q, which cross-links RAGE and LAIR-1 and polarizes monocytes to an antiinflammatory phenotype. These findings may provide a mechanism to control nonresolving inflammation in many pathologic conditions.
Identifiants
pubmed: 31570601
pii: 1907490116
doi: 10.1073/pnas.1907490116
pmc: PMC6859319
doi:
Substances chimiques
Ager protein, mouse
0
HMGB1 Protein
0
HMGB1 protein, mouse
0
Interferon Regulatory Factors
0
Irf5 protein, mouse
0
Receptor for Advanced Glycation End Products
0
Receptors, Immunologic
0
leukocyte-associated immunoglobulin-like receptor 1
0
Leukotriene B4
1HGW4DR56D
Complement C1q
80295-33-6
Arachidonate 5-Lipoxygenase
EC 1.13.11.34
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
23254-23263Subventions
Organisme : NHLBI NIH HHS
ID : R35 HL145228
Pays : United States
Organisme : NIAID NIH HHS
ID : P01 AI102852
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL127464
Pays : United States
Organisme : NIAMS NIH HHS
ID : K01 AR065506
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI135063
Pays : United States
Organisme : NIGMS NIH HHS
ID : R35 GM118182
Pays : United States
Commentaires et corrections
Type : CommentIn
Déclaration de conflit d'intérêts
The authors declare no competing interest.
Références
Nature. 2014 Jun 5;510(7503):92-101
pubmed: 24899309
PLoS One. 2014 Jul 30;9(7):e103478
pubmed: 25076492
Head Neck. 2019 Apr;41(4):1080-1086
pubmed: 30549148
J Exp Med. 2013 Oct 21;210(11):2447-63
pubmed: 24081950
Exp Ther Med. 2016 Dec;12(6):3699-3705
pubmed: 28105100
Int Immunol. 2018 Oct 29;30(11):529-536
pubmed: 29860420
Basic Clin Pharmacol Toxicol. 2014 Jan;114(1):70-7
pubmed: 23953428
Immunity. 2014 Mar 20;40(3):315-27
pubmed: 24656045
Neurobiol Dis. 2010 Mar;37(3):503-9
pubmed: 19833208
Curr Cardiol Rev. 2008 May;4(2):116-22
pubmed: 19936286
FASEB J. 2013 Aug;27(8):3306-14
pubmed: 23603839
Annu Rev Immunol. 2011;29:139-62
pubmed: 21219181
Cancer Res. 2002 Aug 15;62(16):4805-11
pubmed: 12183440
Nat Immunol. 2011 Mar;12(3):231-8
pubmed: 21240265
Science. 2001 Nov 30;294(5548):1871-5
pubmed: 11729303
J Immunol Res. 2018 Oct 21;2018:5264195
pubmed: 30420970
Arthritis Rheum. 2012 Mar;64(3):788-98
pubmed: 21968701
Nat Rev Drug Discov. 2016 Aug;15(8):551-67
pubmed: 27020098
J Immunol. 2011 Nov 15;187(10):5408-18
pubmed: 22013115
J Biol Chem. 2000 Aug 18;275(33):25372-80
pubmed: 10837478
Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1660-5
pubmed: 20080636
Lipids Health Dis. 2011 May 15;10:76
pubmed: 21569625
J Clin Invest. 2018 Jul 2;128(7):2680-2690
pubmed: 30108195
Cell Rep. 2016 Aug 30;16(9):2442-55
pubmed: 27545875
Nat Commun. 2016 Feb 01;7:10346
pubmed: 26831747
Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12165-70
pubmed: 14530386
Am J Pathol. 2010 Oct;177(4):1576-91
pubmed: 20813960
J Immunol. 2014 Jun 15;192(12):5459-68
pubmed: 24907379
Nature. 2005 Mar 10;434(7030):243-9
pubmed: 15665823
Eur J Immunol. 2012 Jun;42(6):1477-87
pubmed: 22678902
J Neuroinflammation. 2006 May 11;3:12
pubmed: 16689995
Curr Drug Targets. 2010 Jul;11(7):882-7
pubmed: 20388065
J Exp Med. 1996 Jan 1;183(1):137-46
pubmed: 8551217
J Immunol. 2019 Feb 1;202(3):920-930
pubmed: 30593537
Adv Drug Deliv Rev. 2013 Oct;65(10):1357-69
pubmed: 23026637
Proc Natl Acad Sci U S A. 2016 Oct 25;113(43):12232-12237
pubmed: 27791009
Sci Rep. 2019 Apr 11;9(1):5936
pubmed: 30976041
Nat Genet. 2006 May;38(5):550-5
pubmed: 16642019
Circulation. 2017 Sep 19;136(12):1140-1154
pubmed: 28698173
J Rheumatol. 1992 Feb;19(2):252-8
pubmed: 1321246
Transl Res. 2016 Jan;167(1):167-82
pubmed: 26207886
Cell. 2011 Apr 29;145(3):341-55
pubmed: 21529710
Nat Med. 2015 Jun;21(6):610-8
pubmed: 25939064
Mol Immunol. 2017 Sep;89:73-83
pubmed: 28601358
Immunity. 2014 Jul 17;41(1):14-20
pubmed: 25035950
Nat Immunol. 2007 May;8(5):487-96
pubmed: 17417641
Immunol Res. 2015 Dec;63(1-3):101-6
pubmed: 26410546
Ann Rheum Dis. 2008 May;67(5):727-8
pubmed: 18408114
Nat Commun. 2016 Sep 23;7:12859
pubmed: 27659679
J Immunol. 2015 Feb 15;194(4):1467-79
pubmed: 25595782
Front Immunol. 2018 Aug 28;9:1938
pubmed: 30210495
Arch Biochem Biophys. 1998 Aug 1;356(1):71-6
pubmed: 9681993
FASEB J. 2013 Jun;27(6):2220-32
pubmed: 23407709
J Clin Invest. 2018 Jul 2;128(7):2657-2669
pubmed: 29757195
Kidney Int. 1991 Jan;39(1):95-102
pubmed: 1848329
Mol Med. 2015 Feb 05;20:559-68
pubmed: 25247291
Proc Natl Acad Sci U S A. 2014 Oct 7;111(40):14530-5
pubmed: 25246560
Cell Metab. 2014 Jan 7;19(1):21-36
pubmed: 24239568
Immunity. 1997 Aug;7(2):283-90
pubmed: 9285412
Macrophage (Houst). 2015;2(1):null
pubmed: 26082946
J Biol Chem. 2009 Jan 2;284(1):306-13
pubmed: 18978352
Proc Natl Acad Sci U S A. 2012 Nov 13;109(46):E3160-7
pubmed: 23093673
Vascul Pharmacol. 2019 Jul - Aug;118-119:106559
pubmed: 30954689
Innate Immun. 2016 Apr;22(3):186-95
pubmed: 26878867
J Clin Invest. 2018 Jul 2;128(7):2713-2723
pubmed: 30108191
J Rheumatol. 1995 Mar;22(3):462-8
pubmed: 7783062
Inflamm Res. 2014 Oct;63(10):885-93
pubmed: 25091012
FASEB J. 2016 May;30(5):1811-22
pubmed: 26813973
Arthritis Care Res (Hoboken). 2015 Oct;67(10):1440-52
pubmed: 25778500
Medicine (Baltimore). 2018 Jul;97(29):e11531
pubmed: 30024540
J Biol Chem. 2007 Mar 30;282(13):9323-34
pubmed: 17244615
Front Immunol. 2017 Nov 01;8:1400
pubmed: 29163481
Blood. 2016 Nov 3;128(18):2218-2228
pubmed: 27683415